$0,17
▲ +$0,01
(+4,29%)
Vol. 3.3M
3
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$12.2M
ROE
-366,6%
Margine
-1383,5%
D/E
536,51
Beta
-2,67
52W
$1–$21
Consenso Wall Street
6 analisti · Apr 20260
Acquisto forte
0
Compra
3
Mantieni
1
Vendi
2
Vendita forte
0,0%
Rating Compra
Grafico dei Prezzi
Titoli simili
RNAC
Cartesian Therapeutics Inc
$187.5M
WHWK
Whitehawk Therapeutics Inc
$114.1M
NKTX
Nkarta Inc
$131.4M
ABOS
Acumen Pharmaceuticals Inc
$127.8M
VTVT
vTv Therapeutics Inc
$167.1M
IMUX
Immunic Inc
$64.2M
TNYA
Tenaya Therapeutics Inc
$154.0M
HRTX
Heron Therapeutics Inc
$238.4M
UNCY
Unicycive Therapeutics Inc
$124.0M
Utili
Tasso di battuta: 100,0%
Prossimo report
Mag 12, 2026
Stima EPS: $-0,31
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,31 | — | — |
| Set 2025 | $-1,47 | $-0,86 | +$0,61 |
| Giu 2025 | $-1,74 | $-1,71 | +$0,03 |
| Mar 2025 | $-2,07 | $-1,41 | +$0,66 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Ricavi | — | — | — | — | — |
| Utile netto | -$8.9M | -$8.2M | -$8.9M | -$11.2M | -$7.6M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -366.6% | -366.6% | -366.6% | -366.6% | -366.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -1383.5% | -1383.5% | -1383.5% | -1383.5% | -1383.5% |
| Gross Margin | — | 31.0% | 31.0% | 31.0% | 31.0% | 31.0% |
| D/E Ratio | — | 536.51 | 536.51 | 536.51 | 536.51 | 536.51 |
| Current Ratio | — | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 |
Rapporti chiave
ROA (TTM)
-64,9%
P/S (TTM)
2,12
P/B
3,4
EPS (TTM)
$-5,94
CF/Share
$-21,40
52W High
$20,60
52W Low
$0,51
$0,51
Intervallo 52 settimane
$20,60
Salute finanziaria
Flusso di cassa libero
-$10.9M
Debito netto
$8.8M
Liquidità
$21.1M
Debito totale
$29.9M
Aggiornato al Set 30, 2025
Як KALA виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка KALA vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
2,1
▼
84%
sotto
peer
(12,9)
vs Peer
vs Settore
Sottovalutato
P/B
3,4
▲
39%
sopra
peer
(2,5)
vs Peer
vs Settore
Più costoso
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість KALA vs аналоги Biotechnology
ROE
-366,6%
▼
445%
sotto
peer
(-67,3%)
vs Peer
vs Settore
Debole
Net margin
-1383,5%
▼
382%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
31,0%
▼
61%
sotto
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
-64,9%
▼
39%
sotto
peer
(-46,7%)
vs Peer
vs Settore
Debole
Фінансове здоровʼя KALA vs аналоги Biotechnology
D/E ratio
536,5
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
2,0
▼
55%
sotto
peer
(4,4)
vs Peer
vs Settore
Liquidità bassa
Beta
-2,7
▼
376%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів KALA
KALA
Mediana peer
Industria
KALA прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio